Literature DB >> 3439192

Metabolism of nilvadipine, a new dihydropyridine calcium antagonist, in rats and dogs.

S Terashita1, Y Tokuma, T Fujiwara, Y Shiokawa, K Okumura, H Noguchi.   

Abstract

1. The metabolic profiles of nilvadipine in the excreta of male rats and dogs were studied after i.v. and oral dosing. Six types of metabolites were isolated and identified from the urine of male rats and dogs or bile of rats. 2. Several metabolites were detected in the urine (12) and bile (17) of rats by two-dimensional t.l.c., after dosing with 14C-nilvadipine. The metabolic profiles in the excreta of rats and dogs were qualitatively similar but quantitative differences were observed. 3. The main metabolites were products of (i) oxidation of the 1,4-dihydropyridine ring to the corresponding pyridine, (ii) hydrolysis of the 5-isopropyl ester or 3-methyl ester group to carboxylic acid, and/or (iii) hydroxylation of the 6-methyl group or methyl group of the isopropyl ester chain. 4. Minor metabolites were products of hydrolysis from the 5-isopropyl ester to the carboxylic acid having a dihydropyridine ring, or reduction of the 3-nitro group of the phenyl moiety having a pyridine ring.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3439192     DOI: 10.3109/00498258709044002

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  3 in total

Review 1.  Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore.

Authors:  Fraser F Fleming; Lihua Yao; P C Ravikumar; Lee Funk; Brian C Shook
Journal:  J Med Chem       Date:  2010-08-30       Impact factor: 7.446

2.  Urinary excretion of the 1,4-dihydropyridine calcium antagonist VULM 993 and its metabolites in the rat.

Authors:  M Stefek; V Faberova; S Musil; I Kakalik
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

3.  Multicomponent mapping of boron chemotypes furnishes selective enzyme inhibitors.

Authors:  Joanne Tan; Armand B Cognetta Iii; Diego B Diaz; Kenneth M Lum; Shinya Adachi; Soumajit Kundu; Benjamin F Cravatt; Andrei K Yudin
Journal:  Nat Commun       Date:  2017-11-24       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.